AUTHORS
Mansi Ramesh Shah, MD, Lin Wang, MD, PhD2, Teofilia Acheampong3, Claudia Castro-Dickson, MS, PharmD4, Sikander Ailawadhi, MD5
AFFILIATIONS
1 Rutgers Cancer Institute, New Brunswick, New Jersey, United States
2 Bristol Myers Squibb, Princeton, New Jersey, United States
3 Bristol Myers Squibb, Princeton, New Jersey, United States
4 Bristol Myers Squibb, Princeton, New Jersey, United States
5 Mayo Clinic, Jacksonville, Florida, United States
ABSTRACT
Introduction: Nearly all patients with multiple myeloma (MM) become exposed or refractory to standard therapy. Clinical outcomes are particularly poor for patients with relapsed or refractory MM (RRMM) who are quadruple-class exposed (QCEx) to immunomodulatory drugs, proteasome inhibitors, anti-CD38 monoclonal antibodies, and B-cell maturation antigen–targeted therapies. The impact of rapid progression and therapeutic futility on patient outcomes and health care expenditure remains largely unquantified.
Methods: This retrospective cohort study used the Optum® Clinformatics® Data Mart claims database (January 1, 2007, through December 31, 2025) to identify patients with RRMM and ≥3 prior lines of therapy (LoT) who were QCEx (ICD-9-CM 203.0x or ICD-10-CM C90.0x) and started a subsequent (index) line, with index date defined as index line start. Outcomes included patient/disease characteristics, treatment patterns, time to next treatment or death, and all-cause and MM-attributed health care resource utilization (HCRU) and costs, assessed per-patient-per-month (PPPM) and cumulatively over follow-up.
Results: Among 164 patients (median follow-up of 9.0 months [range, 0.1–50.9]), median age at index was 71 years and Charlson Comorbidity Index was ≥5 in 80.5% of patients. Median number of prior LoT was 5 (range, 3–15) and 42.7% of patients were quadruple-class refractory. The index line began in 2023 or later for 75.6% of patients. Talquetamab (21.3%) and teclistamab (11.0%) were the most frequent index therapy, with no other regimen exceeding 4%. Median time to next treatment was 7.4 months (95% CI, 5.1–11.2). Following the index line, 69 of 164 patients (42.1%) received one subsequent LoT, 28 (17.1%) a second, and 11 (6.7%) a third. Mortality without subsequent therapy increased with each LoT from 36 of 164 patients (22.0%) at the index line to 8 of 28 patients (29%) by index+2.
Across all patients, the all-cause HCRU was 9.4 mean encounters PPPM (97 mean cumulative encounters; range, 3–428) during follow-up, led by outpatient visits (5.3 mean PPPM, 99.4% of patients; 54 mean cumulative) and pharmacy claims (3.5 mean PPPM, 97.0%; 39 mean cumulative); 67.1% were hospitalized (mean stay of 10.1 days [range, 1–88]), 64.6% used the emergency room, 43.9% underwent a transplant or transfusion, and 31.7% required intensive care unit (ICU) stays during hospitalization (mean ICU stay of 10.1 days [range 1–33]). Among patients who incurred each encounter type, outpatient mean patient visits peaked at 17.2 in the first 3 months and remained elevated at 12.2 at 3–6 months and 10.3 at 15–18 months; pharmacy visits similarly persisted, ranging from 10.3 mean patient visits at 0–3 months to 7.7 at 15–18 months; both inpatient and emergency room mean patient visits, while low, were persistent (1-2 per time interval).
Mean all-cause cost was $52,290 PPPM, led by outpatient care ($32,589), followed by inpatient care ($11,910, including $1873 ICU costs) and pharmacy claims ($7080); emergency room ($711) and transplant or transfusion costs ($640, subsumed within the above categories) were modest. MM-attributed costs were ~95% of all-cause spending ($49,454 PPPM), exceeding 90% each for outpatient, inpatient (including ICU), and transplant or transfusion, versus 88% for pharmacy and 76% for emergency room. Over the full follow-up, mean total all-cause cost per patient was $503,211 (range, $6927–$3,488,640), driven by outpatient care ($348,405 cumulative) with inpatient ($94,526) and pharmacy ($55,996) contributing less; MM-attributed cost was $470,878 (~94%).
Conclusions: Patients with QCEx RRMM and ≥3 prior lines of therapy experience rapid progression, steep attrition, and high mortality, with no established standard of care; bispecific antibodies (bsAbs) anchor treatment but deliver only short-lived control, and death frequently precedes the next LoT. High expenditures persist beyond the initial step-up dosing period, reflecting the ongoing monitoring demands inherent to the mechanism of action and safety profile of bsAbs. Despite substantial patient attrition, HCRU and costs remain high over short treatment intervals largely MM-attributed driven by outpatient infusion/monitoring and pharmacy claims. These findings highlight a critical gap between HCRU intensity and treatment durability in this QCEx RRMM patient population and underscore the need for therapies that can deliver more treatment longevity.
DISCLOSURES
Mansi Ramesh Shah, MD: Johnson and Johnson - Honoraria; Pfizer - Honoraria; Bristol Myers Squibb - Honoraria; Regeneron Pharmaceuticals, Inc. - Honoraria; Janssen - Honoraria; Regeneron Pharmaceuticals, Inc. - Research Funding; Abbvie - Research Funding; Johnson and Johnson - Research Funding; Bristol Myers Squibb - Research Funding; Janssen - Research Funding; CellCentric - Research Funding; Pfizer - Consultancy (Includes expert testimony); Targeted Oncology - Consultancy (Includes expert testimony); Regeneron Pharmaceuticals, Inc. - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony)